Electrocore, Inc. (ECOR) Stock Price & Analysis
Electrocore, Inc. (ECOR) fell 2.75% to USD 6.19 as of July 25, 2026 at 13:43 UTC, according to Nexqual real-time market data.
ECOR last closed at USD 6.37; the session ranged USD 5.95–6.53 on volume of 30,064 shares. Market capitalization is $51.35M, with a 52-week range of USD 4.16–10.5 (NCM). Source: Nexqual, July 25, 2026 at 13:43 UTC.
Key Statistics (as of July 25, 2026 at 13:43 UTC)
| Price | USD 6.19 |
|---|---|
| Change | ▼ 2.75% (down) |
| Previous Close | USD 6.37 |
| Open | USD 6.53 |
| Day Range | USD 5.95 – 6.53 |
| 52-Week Range | USD 4.16 – 10.5 |
| Volume | 30,064 shares |
| Market Cap | $51.35M |
| Exchange | NCM |
Technical Analysis (ECOR)
Nexqual's technical model rates ECOR "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 13:43 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 37.83 (neutral) |
| vs SMA50 | Below (USD 7.8) |
| MACD | -0.54 (negative) |
Analyst Ratings (ECOR)
Wall Street analysts rate ECOR "Strong Buy" based on 5 analysts, with a mean price target of USD 19.57 (range USD 12–26), per Nexqual as of July 25, 2026 at 13:43 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 19.57 |
| High Target | USD 26 |
| Low Target | USD 12 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (ECOR)
| Next Earnings Date | 2026-08-05 |
|---|---|
| Revenue Estimate | $9.49M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.59 vs est -0.61 ▲ beat |
| 2025-12-31 | USD -0.34 vs est -0.39 ▲ beat |
| 2025-09-30 | USD -0.4 vs est -0.4 ▲ beat |
| 2025-06-30 | USD -0.44 vs est -0.33 ▼ miss |
Source: Nexqual, July 25, 2026 at 13:43 UTC.
Financials & Fundamentals (ECOR)
| Total Revenue | $34.90M |
|---|---|
| Revenue Growth (YoY) | +42.60% |
| Gross Margin | +87.25% |
| Operating Margin | -55.47% |
| Profit Margin | -44.08% |
| Current Ratio | 1.02 |
| Total Cash | $8.83M |
| Total Debt | $9.48M |
| Free Cash Flow | $-869,750 |
Source: Nexqual, July 25, 2026 at 13:43 UTC.
Financial Health Score (ECOR)
Nexqual rates Electrocore, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 13:43 UTC.
| Growth | Strong — Revenue +27% YoY (annual) |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Mixed — $9M cash vs $9M debt |
| Cash Flow | Weak — FCF negative: -$870K, burning cash |
| Efficiency | Mixed — No data |
Ownership (ECOR)
| Insider Ownership | +32.40% |
|---|---|
| Institutional Ownership | +8.44% |
| Shares Outstanding | 8.30M |
| Float | 5.20M |
| Short % of Float | +4.68% |
Source: Nexqual, July 25, 2026 at 13:43 UTC.
Leadership (ECOR)
Electrocore, Inc. is led by Joshua S. Lev (age 40), CFO & Interim President, per Nexqual as of July 25, 2026 at 13:43 UTC.
| CFO & Interim President | Joshua S. Lev (age 40) |
|---|---|
| Chief Operating Officer | Michael Fox |
| Vice President of Sales & New Market Development | Mitch Deshon |
| Vice President of HR & Employee Success | Jennifer A. Hayes |
Major Backers & Investors (ECOR)
Notable institutional backers of Electrocore, Inc. include Balyasny Asset Management LP, Fidelity, Jaffetilchin Investment Partners, LLC, according to Nexqual as of July 25, 2026 at 13:43 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Balyasny Asset Management LP | 1.29% |
| Fidelity | 0.69% |
| Jaffetilchin Investment Partners, LLC | 0.65% |
| Wealthspire Advisors, LLC | 0.53% |
| Renaissance Technologies | 0.49% |
| International Assets Investment Management, LLC | 0.4% |
| HighTower Advisors, LLC | 0.39% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 4.93% |
| Geode Capital | 0.87% |
| BlackRock | 0.45% |
Source: Nexqual, July 25, 2026 at 13:43 UTC.
From Electrocore, Inc.'s Latest SEC 10-K Filing (filed 2026-03-19)
Key Strengths & Strategy (as disclosed to the SEC)
- electroCore, Inc., a bioelectronic technology medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally.
- The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.
- It also develops Truvaga 350, a personal use consumer electronics general wellness product and Truvaga Plus, an app-enabled general wellness product.
- It also offers non-invasive bioelectronic therapies for the treatment of chronic pain and wellness conditions.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PRPO | Precipio, Inc. | USD 23.68 | ▲ 0.85% |
| ATHE | Alterity Therapeutics Limited | USD 4.54 | ▼ 3.4% |
| TTOO | T2 Biosystems, Inc. | USD 0 | ▼ 77.78% |
| DARE | Dare Bioscience, Inc. | USD 1.28 | ▲ 4.92% |
| COCP | Cocrystal Pharma, Inc. | USD 0.9 | ▼ 4.24% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 13:43 UTC. This page is informational and not investment advice.